Navigation Links
arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients
Date:1/13/2014

>

About the ARGX-110 Study

The Phase Ib study (ClinicalTrials.gov Identifier: NCT01813539) consists of a dose escalation phase followed by adaptive safety and efficacy expansion cohorts conducted in patients with advanced, refractory cancer. The patient enrichment strategy relies on individual tumor screening for CD70 utilizing a reproducible immunohistochemistry method. In addition to traditional clinical and PK/PD endpoints, biomarkers documenting the three modes of action of ARGX-110 are being evaluated. Patient enrolment is planned at approximately 90 CD70-positive patients with either haematological or solid tumors. The study is managed jointly by arGEN-X and a consortium of leading academic institutions in Belgium.

About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

http://www.argen-x.com

About IWT

The agency for Innovation by Science and Technology (abbreviated as IWT) is the government agency founded in 1991 by the Flemish Government to support technological innovation projects in Flanders. Each year IWT distributes about EUR 300 million in subsidies for innovation projects to companies, organizations, research and educational institutions in Flanders. In addition to financial support, IWT also assists companies by, for instance helping them find the right information or the right partners at home or abroad, providing assistance with the preparation of projects for European programmes and with technology transfer throughout Europe. IWT
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
5. arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
6. Russian Government Starts Using Scopus for National Research Assessment
7. John Daly, Previous Merck Exec., Starts CTW Consulting Firm
8. FDA starts process to cut back antibiotic overuse in livestock
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... NEW YORK, Jan. 25, 2011 Reportlinker.com ... is available in its catalogue: ... analysis of small molecule brand erosion post-patent ... IntroductionPharma is facing slowing ...
... 2011 Prolong Pharmaceuticals, which in October secured a ... today announced the signing of a long term lease ... and the formal addition of Dr. Hemant Misra to ... and Facilities Operations. The manufacturing facility ...
Cached Medicine Technology:Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team 2
(Date:7/11/2014)... 2014 The American Association of Poison ... centers are commending Senator Bill Nelson (D-FL) for his ... 2014 on July 10, 2014. Along with fellow Senate ... Commission (CPSC) to enact rules requiring safer, child-resistant packaging ... , Senate co-sponsors of the bill include: Sen. Richard ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... News) -- People with the lowest incomes may have a ... (PAD), a new study suggests. People with PAD have ... most often the legs. The condition causes leg pain and ... the body. People with PAD have a higher risk for ... 6,800 people with PAD who took part in the U.S. ...
(Date:7/11/2014)... 2014 Microbiology testing is a highly ... industry, which is expected to pose the biggest challenge ... owes its growth to the ongoing spread of AIDS ... and a major factor leading to the upsurge of ... and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3
... testing breast tumors for HER2 ( http://www.mayoclinic.com/health/breast-cancer/AN00495 ) proteins ... of tumor (a single tumor block) is analyzed. However, ... ( http://www.mayoclinic.org/ ) found that HER2 results can vary ... tumor blocks are analyzed. This could have significant ...
... News) -- Americans who live in walkable neighborhoods are ... a higher quality of life, a new study suggests. ... stroll to such destinations as parks and playgrounds, club ... coffee shops and restaurants, explained study author Shannon Rogers ...
... from a specialized scan, radiation oncologists at Mayo Clinic ... number of lymph nodes critical for removing fluid from ... VIDEO ALERT: Additional audio and video resources, including excerpts ... researchers presenting at San Antonio Breast Cancer Symposium, are ...
... GeparQuinto study, randomized Phase III efficacy data on the ... early breast cancer will be presented at the 33rd ... von Minckwitz, M.D., Ph.D., managing director of the German ... efficacy data from this study, which will detail the ...
... Dec. 10 (HealthDay News) -- Children and teens accounted for ... treated in U.S. emergency departments between 1997 and 2006, a ... such heat-related injuries also increased 133 percent during the study ... according to the researchers at the Center for Injury Research ...
... of circulating tumor cells (CTCs) cells that have detached ... the blood are an independent prognostic marker in metastatic ... CTC level during therapy was found to be an early ... series validating the prognostic value of CTCs in first-line chemotherapy ...
Cached Medicine News:Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 2Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 3Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 4Health News:'Walkable' Communities More Close-Knit, Study Finds 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 3Health News:Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented 2Health News:Children, Teens Account for Half of Exercise-Related Heat Injuries 2Health News:High CTC levels predicted poor outcome in metastatic breast cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: